The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.
 
Khalid Jazieh
Stock and Other Ownership Interests - Innovative Healthcare Institute (I)
Research Funding - Natera (I)
 
Hani Babiker
Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
 
Nathan Foster
No Relationships to Disclose
 
Briant Fruth
No Relationships to Disclose
 
Ryan Carr
No Relationships to Disclose
 
Steven Alberts
No Relationships to Disclose
 
Caitlin Conboy
No Relationships to Disclose
 
Nguyen Tran
Honoraria - Helsinn Therapeutics (Inst); QED Therapeutics (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); QED Therapeutics (Inst); TEMPUS (Inst)
Research Funding - Exact Sciences
 
Mindy Hartgers
No Relationships to Disclose
 
Thorvardur Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Jason Starr
Consulting or Advisory Role - Exelixis
Research Funding - Amgen (Inst); Aminex (Inst); Arcus Biosciences (Inst); Camurus (Inst); RayzeBio (Inst); Viewpoint Molecular Targeting (Inst)
 
Mohamad Sonbol
Honoraria - Novartis
Research Funding - Lilly (Inst); Taiho Oncology (Inst)
 
Jeremy Jones
No Relationships to Disclose
 
Daniel Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Incyte; Incyte; Novartis
Research Funding - AstraZeneca; Bayer
 
Lionel Aurelien Kankeu Fonkoua
Honoraria - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
 
Christina Wu
Honoraria - Cancer Treament Centers of America; Medscape
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Exelixis; Natera; Natera; Nova Research Company; Pfizer; Seagen
Research Funding - HUTCHMED; Pfizer; Sirnaomics (Inst); Sumitomo Pharma (Inst)
 
Katrina Pedersen
Honoraria - OncLive/MJH Life Sciences; Takeda; WebMD/Medscape; WebMD/Medscape (Inst)
Consulting or Advisory Role - Agenus; Array BioPharma; Artemida Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; GlaxoSmithKline; Guardant Health; Incyte; Novartis; Pfizer; SAGA Diagnostics; Taiho Oncology; Taiho Oncology; Takeda (Inst); Tempus
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Biomea Fusion (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Daiichi Sankyo/Lilly (Inst); HCW Biologics (Inst); Incyte (Inst); Ipsen (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Array BioPharma; BeiGene; GlaxoSmithKline; NCCN; Nouscom
Other Relationship - UpToDate
(OPTIONAL) Uncompensated Relationships - NCCN
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Robert McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Zentalis
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)